Pyridine-sulfonamide derivatives as sodium channel inhibitors

Patent metadata

Field	Value
Publication number	US-12209075-B2
Application number	US-201917056325-A
Country	US
Kind code	B2
Filing date	May 21, 2019
Priority date	May 22, 2018
Publication date	Jan 28, 2025
Grant date	Jan 28, 2025

Abstract

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y 1 -Y 6 , X, Z, Z 1 , Z 2 , R 2 -R 3 , and R 6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. The compounds have sodium channel blocking activity that are useful for treating sodium channel-mediated diseases, in particular for treating pain.

First claim

We claim:

1. A compound of formula I, or pharmaceutically acceptable salt thereof,

R 9 is methyl or two R 9 substituents and the nitrogen to which they are attached are pyrrolidine; and:

is selected from the group consisting of:

2. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Assignees

• Genentech Inc

Inventors

• Mckerrall Steven
• Beveridge Ramsay
• Lai Kwong Wah
• Bergeron Philippe

Classifications

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61P17/04

  Antipruritics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title